From May 21-23, 2025, the 92nd China International Pharmaceutical Raw Materials/Intermediates/Packaging/Equipment Exhibition (API China) was grandly held in Guangzhou. As one of Asia's most influential pharmaceutical ingredient industry events, this exhibition attracted participation from renowned pharmaceutical companies and biotech firms worldwide. Eternity Biotechnology made a stunning appearance with its core product Antrodia cinnamomea, becoming a highlight of the exhibition due to its exceptional quality and innovative technology, earning high praise and numerous cooperation intentions from domestic and international buyers.
Antrodia Cinnamomea: The "Ruby of the Forest"
Antrodia cinnamomea, also known as "niu zhang gu" or "zhang zhi," is a rare medicinal fungus unique to Taiwan. It grows only in the hollow interiors or on the damp surfaces of fallen trunks of Cinnamomum kanehirae trees at altitudes of 450 to 2,000 meters. Due to its harsh growing environment, slow growth rate, scarce wild resources, and rich bioactive components such as triterpenoids, polysaccharides, and superoxide dismutase (SOD), it is hailed by academia as the "King of Medicinal Mushrooms." Its vibrant orange-red color has also earned it the title "Ruby of the Forest." Traditional Chinese medicine recognizes its liver-protecting, antioxidant, and immune-regulating properties, while modern research has further confirmed its potential in anti-tumor, anti-inflammatory, and metabolic disease applications. Given the scarcity of wild Antrodia cinnamomea, artificial cultivation technology has become key to the industry's development.
Eternity Biotechnology: A Practitioner of Empowering Traditional Medicine with Technology
Eternity Biotechnology Co., Ltd. is a biotechnology company focused on the extraction, development, and application of natural plant ingredients, dedicated to transforming nature's precious resources into efficient and safe health products. The company brings together outstanding experts and elites from Taiwan, mainland China, and Hong Kong, forming a cross-disciplinary professional team spanning biotechnology, pharmacology, agricultural technology, and other fields. With strong R&D capabilities and an innovative spirit, the company continues to break through technical bottlenecks, advancing the application of natural plant ingredients to new heights. Through deep "industry-academia-research" collaboration with top universities and research institutions across the strait, Eternity has successfully overcome the technical challenges of artificial Antrodia cinnamomea cultivation, achieving large-scale, stable production of high-quality fruiting bodies.
Core Technological Advantages: Full-Chain Innovation from Strains to Products
1. Premium Strains: In collaboration with renowned domestic research centers, Eternity has screened strains with high active ingredient content and optimal characteristics through continuous analysis and experimentation, ensuring product stability and efficacy.
2. Fifth-Generation Bionic Cultivation Process: Unlike traditional log cultivation, liquid cultivation, solid cultivation, or plate cultivation, Eternity's bionic cultivation system simulates the natural growth environment of Cinnamomum kanehirae trees, enabling artificially cultivated fruiting bodies to achieve triterpenoid content levels comparable to wild varieties, significantly surpassing industry standards.
3. New Patents: Through continuous optimization and innovation in the production process, the company has obtained domestic patents, enhancing its technological reserves as well as the quality and yield of Antrodia cinnamomea.
4. WMS Cultivation Management System: The self-developed system manages all production processes, achieving scientific data analysis, standardized operational procedures, and systematic management integration. This not only improves production efficiency and product quality but also establishes a replicable foundation for future development.
Exhibition Highlights: International Buyers Praise and Strong Cooperation Interest
During the exhibition, Eternity's booth attracted hundreds of professional buyers from mainland China, Southeast Asia, Europe, and America with its unique products and innovative technology. Many buyers noted that Eternity's technical capabilities and standardized production capacity address the industry's pain point of unstable Antrodia cinnamomea supply, providing a reliable option for pharmaceutical and functional food development.
Cheng Xiaohua, Business Director of Eternity Biotechnology, stated in an interview: "This exhibition marks an important step in our market expansion. In the future, we will continue to deepen technological R&D and plan to collaborate with mainland hospitals and pharmaceutical companies to jointly develop innovative products for liver disease, immune regulation, and other areas."
Future Outlook: Promoting the Globalization of the Antrodia Cinnamomea Industry
With the booming health industry and growing demand for natural medicines, Eternity Biotechnology has successfully showcased its innovation capabilities to the world through API China. The company revealed that its next step will be to accelerate overseas market expansion, allowing this Eastern treasure to benefit a broader global consumer base.